Pelacarsen for Cardiovascular Disease
(ADD-VANTAGE Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
The purpose of the study CTQJ230A12304, is to evaluate the efficacy, safety, and tolerability of pelacarsen (TQJ230) compared to placebo in participants with ASCVD who have elevated lipoprotein(a) (Lp(a)), and who are on background inclisiran treatment for elevated low-density lipoprotein cholesterol (LDL-C).
Are You a Good Fit for This Trial?
This trial is for people with cardiovascular disease who have high levels of a fat-protein particle called Lp(a) and are already taking Inclisiran for high LDL cholesterol. They must have stable heart disease, stroke history, or blocked arteries and be on consistent lipid-lowering therapy and other treatments for related conditions like hypertension or diabetes.Inclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive either pelacarsen or placebo subcutaneous injections once monthly
Open-label Treatment
All participants receive pelacarsen 80 mg injection once monthly
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- Inclisiran
- Pelacarsen
Find a Clinic Near You
Who Is Running the Clinical Trial?
Novartis Pharmaceuticals
Lead Sponsor
Dr. Vas Narasimhan
Novartis Pharmaceuticals
Chief Executive Officer since 2018
MD from Harvard Medical School
Dr. Shreeram Aradhye
Novartis Pharmaceuticals
Chief Medical Officer since 2021
MD